{"transactions":[{"id":901024,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-02-17T16:47:12.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":96150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device."}],"balance_after":96150,"derivative":{"exercise_price":0.4,"underlying":"Class A Common Stock","underlying_shares":96150},"source":{"system":"sec-edgar","filing":"0000914190-26-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000091419026000026/form4.xml","form_type":"4"}},{"id":901023,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-02-17T16:47:12.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":57690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device."}],"balance_after":57690,"derivative":{"exercise_price":0.4,"underlying":"Class A Common Stock","underlying_shares":57690},"source":{"system":"sec-edgar","filing":"0000914190-26-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000091419026000026/form4.xml","form_type":"4"}},{"id":901022,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-02-17T16:47:12.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":96150,"price":0.4,"value":38460.0,"ownership":{"direct":true},"balance_after":174037,"source":{"system":"sec-edgar","filing":"0000914190-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000091419026000026/form4.xml","form_type":"4"}},{"id":979024,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T17:40:57.000Z","date":"2025-12-03","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":62500,"derivative":{"exercise_price":0.813,"exercise_date":"2026-05-01","expiration_date":"2035-12-03","underlying":"Class A Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0000914190-25-000049","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000091419025000049/form4.xml","form_type":"4"}},{"id":1321686,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2024-12-26T17:52:27.000Z","date":"2024-12-23","kind":"other","planned":false,"acquired":true,"shares":34705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were received by the reporting person in connection with a pro-rata distribution in-kind by Anzu SPAC GP I LLC to its members for no consideration."}],"balance_after":77887,"source":{"system":"sec-edgar","filing":"0001140361-24-050422","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000114036124050422/form4.xml","form_type":"4"}},{"id":1355763,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-11-21T18:04:00.000Z","date":"2024-11-19","kind":"other","planned":false,"acquired":true,"shares":18182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were received by the reporting person in connection with a pro-rata distribution in-kind by Anzu SPAC GP I LLC to its members for no consideration."}],"balance_after":43182,"source":{"system":"sec-edgar","filing":"0001062993-24-019530","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000106299324019530/form4.xml","form_type":"4"}},{"id":1759023,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-10-17T17:29:20.000Z","date":"2023-10-15","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months."}],"balance_after":62500,"derivative":{"exercise_price":2.4,"expiration_date":"2033-10-15","underlying":"Class A Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001062993-23-019481","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000106299323019481/form4.xml","form_type":"4"}},{"id":1767497,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock, par value $0.0001 per share","published_at":"2023-10-03T21:50:55.000Z","date":"2023-09-29","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock, par value $0.0001 per share","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-23-018935","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000106299323018935/form4.xml","form_type":"4"}},{"id":1767496,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock, par value $0.0001 per share","published_at":"2023-10-03T21:50:55.000Z","date":"2023-09-29","kind":"exercise","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001062993-23-018935","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673071/000106299323018935/form4.xml","form_type":"4"}},{"id":4410595,"issuer":{"id":178276,"kind":"organization","name":"LIONBRIDGE TECHNOLOGIES INC /DE/","symbol":"LIOX"},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"restricted stock units","published_at":"2017-03-02T15:43:56.000Z","date":"2017-02-28","kind":"disposition_to_issuer","acquired":false,"shares":7559,"price":5.75,"value":43464.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. (\"Lionbridge\") and entities affiliated with H.I.G. Capital, LLC (the \"Merger Agreement\").  The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the \"Merger\")."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2017-08-18","underlying":"common stock","underlying_shares":7559},"source":{"system":"sec-edgar","filing":"0001328319-17-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1058299/000132831917000027/edgar.xml","form_type":"4"}},{"id":4410594,"issuer":{"id":178276,"kind":"organization","name":"LIONBRIDGE TECHNOLOGIES INC /DE/","symbol":"LIOX"},"owners":[{"id":66206,"kind":"person","name":"Kantor Susan","position":1,"cik":"0001673071","reported_name":"Kantor Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"stock option (right to buy)","published_at":"2017-03-02T15:43:56.000Z","date":"2017-02-28","kind":"disposition_to_issuer","acquired":false,"shares":27353,"price":1.12,"value":30635.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the effective time of the Merger, each Lionbridge option, whether or not vested and exercisable, outstanding and unexercised immediately prior to the effective time was converted into the right to receive an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $5.75 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of December 12, 2016, by and among Lionbridge Technologies, Inc. (\"Lionbridge\") and entities affiliated with H.I.G. Capital, LLC (the \"Merger Agreement\").  The Merger Agreement provides that each share of Lionbridge common stock and each outstanding restricted stock unit shall be converted into the right to receive $5.75 in cash, without interest (the \"Merger\")."}],"balance_after":0,"derivative":{"exercise_price":4.63,"expiration_date":"2021-07-18","underlying":"common stock","underlying_shares":27353},"source":{"system":"sec-edgar","filing":"0001328319-17-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1058299/000132831917000027/edgar.xml","form_type":"4"}}]}